Modality
mRNA
MOA
AuroraAi
Target
CD19
Pathway
T-cell
NB
Development Pipeline
Preclinical
~May 2017
→ ~Aug 2018
Phase 1
Nov 2018
→ Feb 2031
Phase 1Current
NCT08402918
1,293 pts·NB
2018-11→2027-03·Recruiting
NCT07009582
2,286 pts·NB
2022-08→2031-02·Recruiting
3,579 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-03-2612mo awayPh2 Data· NB
2031-02-274.9y awayPh2 Data· NB
Trial Timeline
Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
P1/2
Recruit…
P1/2
Recruit…
Catalysts
Ph2 Data
2027-03-26 · 12mo away
NB
Ph2 Data
2031-02-27 · 4.9y away
NB
Recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08402918 | Phase 1/2 | NB | Recruiting | 1293 | PFS |
| NCT07009582 | Phase 1/2 | NB | Recruiting | 2286 | eGFR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-8662 | Pfizer | NDA/BLA | CD19 | |
| NVS-6974 | Novartis | Preclinical | CD19 | |
| TAK-5300 | Takeda | Phase 1 | SMN2 | |
| DSN-791 | Daiichi Sankyo | NDA/BLA | Aβ | |
| REG-861 | Regeneron | Phase 2 | PARP | |
| MRN-5715 | Moderna | NDA/BLA | CDK4/6 | |
| BGN-6990 | BeiGene | Phase 2/3 | BCMA | |
| Semasacituzumab | Jazz Pharma | Phase 2 | AHR | |
| ILM-2412 | Illumina | Phase 3 | PLK4 | |
| Tirarelsin | TG Therapeutics | NDA/BLA | CD19 |